AstraZeneca aligns with Regulus for microRNA therapeutics
Anglo-Swedish drug major AstraZeneca (LSE: AZN) and US biotech firm Regulus Therapeutics have signed a strategic alliance for the discovery, development and commercialization of microRNA therapeutics for three exclusive targets which are currently in pre-clinical development.
AstraZeneca will make a payment of $28 million to Regulus including an equity investment and upfront payment. Regulus, which was formed in 2007 by Alnylam Pharmaceuticals and Isis Pharmaceuticals, is also eligible to receive contingent launch and commercial milestone payments and royalties.
Regulus and AstraZeneca will collaborate on three microRNA targets, which include Regulus’ lead cardiovascular/metabolic disease program targeting microRNA-33 for the treatment of atherosclerosis. Regulus will lead preclinical development and, if successful, could receive preclinical milestone payments. AstraZeneca will lead and fund the clinical development and commercialization of these programs.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze